Lantheus Holdings Inc

Stock Chart, Company Information, and Scan Results

$53.79(as of Aug 13, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Lantheus Holdings Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$53.79
Ticker SymbolLNTH
ExchangeNasdaq
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees808
CountyUSA
Market Cap$3,657.4M
EBIDTA494.0M
10-Day Moving Average59.68
P/E Ratio14.13
20-Day Moving Average65.79
Forward P/E Ratio9.19
50-Day Moving Average74.44
Earnings per Share3.76
200-Day Moving Average87.93
Profit Margin20.83%
RSI28.86
Shares Outstanding68.0M
ATR3.57
52-Week High118.21
Volume1,527,114
52-Week Low47.25
Most Recent Support Level51.40
Book Value1,166.8M
Most Recent Resistance Level57.21
P/B Ratio3.28
Upper Keltner73.82
P/S Ratio2.52
Lower Keltner57.75
Debt-to-Equity Ratio73.82
Next Earnings Date10/30/2025
Cash Surplus415.4M
Next Ex-Dividend DateUnknown

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Lantheus Holdings Inc In Our Stock Scanner

As of Aug 15, 2025
example chart graphic
Scan Name: Morning StarScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Heikin Ashi BreakoutScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Oversold Stocks Scan Type: Stock Indicator Scans
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.